Selenium and Vitamin E Supplementation over Recommended Dietary Intake May Raise Prostate Cancer Risk
Results of randomised, placebo-controlled, prevention SELECT trial
In a large clinical trial testing dietary supplements for prostate cancer prevention, baseline selenium status (measured by toenail selenium concentration), in the absence of supplementation, was not associated with prostate cancer risk. However, when baseline toenail selenium concentrations were high, supplementation with high-dose selenium almost doubled the risk of high-grade prostate cancer risk among older men. High-dose vitamin E also more than doubled the risk high-grade prostate cancer risk, but only among men with low baseline toenail selenium concentrations.
These findings, published online 21 February, 2014 in the Journal of the National Cancer Institute, are based on data from the Selenium and Vitamin E Cancer Prevention Trial, or SELECT, a rigorously executed, randomised and placebo-controlled trial conducted by the SWOG cancer research cooperative group that involved more than 35,000 men. The study sought to determine whether taking high-dose vitamin E (400 IU/day) and/or selenium (200 mcg/day) supplements could protect men from prostate cancer.
The trial, which began in 2001 and was designed to last 12 years, stopped early, in 2008, because it found no protective effect from selenium and there was a suggestion that vitamin E increased risk. While use of the study supplements stopped, men were still followed and after an additional two years the men who took vitamin E had a statistically significant 17% increased risk of prostate cancer.
Selenium supplementation increased cancer in men with high selenium status at baseline
When the study started, there was some evidence that selenium supplementation would not benefit men who already had an adequate intake of the nutrient. For that reason, researchers measured the concentration of selenium in participants' toenails and planned to test whether selenium supplementation would benefit only the subset of men with low selenium status at baseline. Instead, they found that taking selenium supplements increased the risk of high-grade cancer by 91% among men with high selenium status at baseline. When selenium supplements were taken by men who had high selenium status to begin with, the levels of selenium became toxic.
Taking vitamin E increased cancer risk in men with low selenium status at baseline
The study also found that only a subgroup of men was at increased risk of prostate cancer from taking vitamin E. Among men with low selenium status at baseline, vitamin E supplementation increased their total risk of prostate cancer by 63% and increased the risk of high-grade cancer by 111%. This explained one of the original SELECT findings, which was that only men who received vitamin E plus a placebo, and not those who received both vitamin E and selenium, had an increased prostate cancer risk. Selenium, whether from dietary sources or supplements, protected men from the harmful effects of vitamin E.
"Many people think that dietary supplements are helpful or at the least innocuous. This is not true," said corresponding and first author Alan Kristal, Dr PH, a faculty member in the Public Health Sciences Division of Fred Hutchinson Cancer Research Center. "We know from several other studies that some high-dose dietary supplements – that is, supplements that provide far more than the daily recommended intakes of micronutrients – increase cancer risk. We knew this based on randomized, controlled, double-blinded studies for folate and beta carotene, and now we know it for vitamin E and selenium."
The data and toenail samples for the current analysis compared the effect of selenium and vitamin E, taken either alone or combined, on prostate cancer risk among 1,739 men who were diagnosed with prostate cancer (489 high-grade prostate cancer cases) and, for comparison purposes, a random sample of 3,117 men without prostate cancer who were matched to the cases by race and age.
The study showed no benefits to any men from either selenium or vitamin E supplements, and for significant proportions of men in the study these supplements were harmful.
"These supplements are popular – especially vitamin E – although so far no large, well-designed and well-conducted study has shown any benefits for preventing major chronic disease," Kristal said.
No known benefits – only risks
"Men using these supplements should stop, period. Neither selenium nor vitamin E supplementation confers any known benefits – only risks," he continued. "While there appear to be no risks from taking a standard multivitamin, the effects of high-dose single supplements are unpredictable, complex and often harmful. Taking a broad view of the recent scientific studies there is an emerging consistency about how we think about optimal intake of micronutrients. There are optimal levels, and these are often the levels obtained from a healthful diet, but either below or above the levels there are risks."
SELECT is the only randomised trial that examined the effects of selenium supplementation among men with selenium levels common in the USA and Canada, and it is the only study that has examined the effects of vitamin E supplementation conditional upon selenium status.
The authors conclude that given the increased risks of prostate cancer observed in their study and lack of evidence of a benefit for other diseases of high public health concern, men older than 55 should avoid supplementation with either vitamin E or selenium at doses that exceed recommended dietary intakes.
In an accompanying editorial, Paul H. Frankel, PhD and colleagues discuss the potential biological mechanisms behind the findings in the SELECT trial and write that intriguing study results stimulate discussion on a variety of points. The editorialists propose some additional considerations regarding the specific selenium and vitamin E formulations, baseline selenium levels in men in different countries, and prevention considerations.
The National Cancer Institute (USA) funded the study, which also involved collaborators at the University of Missouri, the University of Texas, the University of California Irvine, the National Cancer Institute, the University of California San Diego and the Cleveland Clinic.
Kristal AR, Darke AK, Morris JS, et al. Baseline Selenium Status and Effects of Selenium and Vitamin E Supplementation on Prostate Cancer Risk. J Natl Cancer Inst; First published online 22 February 2014, doi: 10.1093/jnci/djt456
Frankel PH, Parker RS, Madsen FC, et al. Baseline Selenium and Prostate Cancer Risk: Comments and Open Questions. J Natl Cancer Ins; First published online 22 February 2014. doi: 10.1093/jnci/dju005
Thank you for rating!
You have already rated this page, you can only rate it once!